OLFM4 Protein, Human (HEK293, His)

OLFM4 protein may promote the proliferation of pancreatic cancer cells by affecting the transition from S phase to G2/M phase, highlighting its role in cancer cell cycle dynamics. In myeloid leukemia cell lines, OLFM4 exhibits dual effects of inhibiting growth and inducing differentiation and apoptosis. OLFM4 Protein, Human (HEK293, His) is the recombinant human-derived OLFM4 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of OLFM4 Protein, Human (HEK293, His) is 490 a.a., with molecular weight of 60-90 kDa.

OLFM4 Protein is implicated in potentially promoting the proliferation of pancreatic cancer cells by facilitating the transition from the S to G2/M phase, underscoring its potential role in the cell cycle dynamics of cancerous cells. Conversely, in myeloid leukemic cell lines, OLFM4 inhibits cell growth while inducing cell differentiation and apoptosis, indicating its dual role in distinct cellular contexts. Additionally, it may contribute to the inhibition of EIF4EBP1 phosphorylation/deactivation, suggesting a potential role in modulating protein translation processes. OLFM4 is known to facilitate cell adhesion, possibly through interactions with cell surface lectins and cadherin. Structurally, OLFM4 exists as a homomultimer with disulfide linkages. It interacts with NDUFA13 and exhibits binding affinity to cell surface lectins, including locutions ricinus communis agglutinin I, concanavalin-A, and wheat germ agglutinin, along with cadherin. The multifaceted functions and interactions of OLFM4 highlight its significance in cellular processes with implications in cancer progression and cell adhesion. Further research is crucial to unravel the precise molecular mechanisms through which OLFM4 modulates diverse cellular functions.

Measured by the ability of the immobilized protein to support the spreading of NIH3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 0.625-1.25 μg/mL, corresponding to a specific activity is 800-1600 U/mg.

Human

HEK293

C-10*His

Q6UX06 (D21-Q510)

10562  [NCBI]

DLGDVGPPIPSPGFSSFPGVDSSSSFSSSSRSGSSSSRSLGSGGSVSQLFSNFTGSVDDRGTCQCSVSLPDTTFPVDRVERLEFTAHVLSQKFEKELSKVREYVQLISVYEKKLLNLTVRIDIMEKDTISYTELDFELIKVEVKEMEKLVIQLKESFGGSSEIVDQLEVEIRNMTLLVEKLETLDKNNVLAIRREIVALKTKLKECEASKDQNTPVVHPPPTPGSCGHGGVVNISKPSVVQLNWRGFSYLYGAWGRDYSPQHPNKGLYWVAPLNTDGRLLEYYRLYNTLDDLLLYINARELRITYGQGSGTAVYNNNMYVNMYNTGNIARVNLTTNTIAVTQTLPNAAYNNRFSYANVAWQDIDFAVDENGLWVIYSTEASTGNMVISKLNDTTLQVLNTWYTKQYKPSASNAFMVCGVLYATRTMNTRTEEIFYYYDTNTGKEGKLDIVMHKMQEKVQSINYNPFDQKLYVYNDGYLLNYDLSVLQKPQ

60-90 kDa

• 
  Greater than 80% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, 5% Trehalose, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US;may vary elsewhere.